Salarius Pharmaceuticals, Inc.
Company Snapshot: Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals, Inc. has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
- May 18 2022 Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
- May 12 2022 Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results
- May 11 2022 Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration
- May 5 2022 Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress